Follow The Filings

ARDX Ardelyx

Ardelyx earnings company data as of 2:00 PM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 3 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by ARDX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ARDX insider trades
  • $1.9M bought by 1 insider
  • None no sales outside a trading plan
  • $2.3M sold by 2 insiders under 10b5-1 plans
  1. Michael Raab CEO
    Planned sale
    $211K 41,668 shares at $5.06 2.4% of stake
    Traded Jul 15 Filed Jul 17
  2. Laura A Williams Chief Patient Officer
    Planned sale
    $490K 81,898 shares at $5.99 18% of stake
    Traded Jun 18 Filed Jun 22
  3. Michael Raab CEO
    Planned sale
    $236K 41,666 shares at $5.67 2.4% of stake
    Traded Jun 15 Filed Jun 17
  4. Michael Raab CEO
    Planned sale
    $262K 41,666 shares at $6.28 2.3% of stake
    Traded May 15 Filed May 19
  5. Michael Raab CEO
    Planned sale
    $262K 41,668 shares at $6.29 2.3% of stake
    Traded Apr 15 Filed Apr 17
  6. Michael Raab CEO
    Planned sale
    $243K 41,666 shares at $5.84 2.2% of stake
    Traded Mar 16 Filed Mar 18
  7. Michael Raab CEO
    Planned sale
    $261K 41,666 shares at $6.26 2.2% of stake
    Traded Feb 24 Filed Feb 25
  8. David M Mott Director
    Buy
    $1.9M 333,333 shares at $5.84 +11% to stake
    Traded Feb 20 Filed Feb 23
  9. Laura A Williams Chief Patient Officer
    Planned sale
    $349K 50,000 shares at $6.98 12% of stake
    Traded Jan 8 Filed Jan 9

Also filed in the last 12 months, not counted as buying or selling: 70 sales to cover taxes, 17 stock grants, and 8 option exercises.

SEC filings

Recent issuer filings from EDGAR, 13 shown.

Filed Form Detail Links
8-K 8.01
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 2.02,7.01,9.01
10-Q
8-K 2.03,9.01
8-K 5.02,5.07
DEFA14A
DEFA14A
SCHEDULE 13G/A —
SCHEDULE 13G —
8-K 2.02,7.01,9.01
10-Q

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.